Shots:

• The five therapies include Tabrecta (capmatinib) for advanced and recurrent unresectable NSCLC, Entresto (sacubitril valsartan sodium hydrate) for chronic HF, Mayzent (siponimod fumaric acid) for secondary PMS- Enerzair (glycopyrronium bromide- indacaterol acetate- mometasone furoate) and Atectura (indacaterol acetate- mometasone furoate) for different forms of asthma
• In 2020, Novartis has received seven approval in Japan which include Zolgensma for SMA and Beovu for wet AMD in addition to these five therapies
• These approval boost Novartis’ pipeline and offers Japanese patients a broad range of novel treatment options targeting their medical needs

Click here to read full press release/ article 

 Ref: Novartis | Image: Novartis